Ingersoll-Rand Inc’s filing revealed that its insider Schiesl Andrew R unloaded Company’s shares for reported $1.15 million on Feb 18 ’25. In the deal valued at $87.05 per share,13,228 shares were sold. As a result of this transaction, Schiesl Andrew R now holds 30,846 shares worth roughly $2.45 million.
Then, Schiesl Andrew R bought 13,228 shares, generating $1,151,495 in total proceeds.
Before that, Scheske Michael J sold 2,531 shares. Ingersoll-Rand Inc shares valued at $246,621 were divested by the VP, Chief Accounting Officer at a price of $97.44 per share. As a result of the transaction, Scheske Michael J now holds 11,910 shares, worth roughly $0.94 million.
Stifel downgraded its Ingersoll-Rand Inc [IR] rating to a Hold from a a Buy in a research note published on November 18, 2024; the price target was decreased to $107 from $112. Morgan Stanley began covering IR with “an Equal-weight” recommendation on September 06, 2024.
Price Performance Review of IR
On Friday, Ingersoll-Rand Inc [NYSE:IR] saw its stock jump 0.11% to $79.32. Over the last five days, the stock has gained 3.38%. Ingersoll-Rand Inc shares have fallen nearly -12.31% since the year began. Nevertheless, the stocks have fallen -11.72% over the past one year. While a 52-week high of $106.03 was reached on 01/31/25, a 52-week low of $65.61 was recorded on 04/08/25. SMA at 50 days reached $77.79, while 200 days put it at $90.51.
Levels Of Support And Resistance For IR Stock
The 24-hour chart illustrates a support level at 78.82, which if violated will result in even more drops to 78.32. On the upside, there is a resistance level at 80.07. A further resistance level may holdings at 80.82. The Relative Strength Index (RSI) on the 14-day chart is 59.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.83, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 10.00%. Stochastics %K at 92.81% indicates the stock is a selling.
The most recent change occurred on March 12, 2024 when Exane BNP Paribas began covering the stock and recommended ‘”a Neutral”‘ rating along with a $92 price target.
